Lucy Charlton

Lucy Charlton is Counsel in Goodwin’s Technology and Life Sciences group. She has experience in advising on a wide range of non-contentious intellectual property and commercial matters, with a focus on life sciences, technology and healthcare sectors. Ms. Charlton advises on transactions, including licenses, collaborations, distribution, manufacturing and R&D projects. She also advises on the intellectual property aspects of corporate transactions.

Ms. Charlton’s experience includes:

• Biocon Biologics on its definitive agreement to acquire Viatris’ Biosimilars assets for up to $3.335 billion
• SynAffix and its selling shareholders on its sale to Lonza. Under the terms of the sale and purchase agreement, Lonza have paid Synaffix’s shareholders an upfront payment of €100 million, with the potential for shareholders to receive an additional payment of up to €60 million contingent on financial performance

Prior to joining Goodwin in 2021, Ms. Charlton was a senior associate at Freshfields Bruckhaus Deringer LLP.